Male Hypogonadism - Drug Pipeline Landscape, 2023

Male Hypogonadism - Drug Pipeline Landscape, 2023

Male Hypogonadism is characterized by a decrease in testosterone level or lack of spermatozoa production or both. When a disorder related to the testes it is called primary hypogonadism or if it related to the hypothalamic-pituitary axis it is called secondary hypogonadism.

Causes of hypogonadism include HIV or AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea.

Symptoms of hypogonadism include fatigue, hot flashes, infertility, decrease in muscle mass, and loss of bone mass

Doctor diagnose hypogonadism based on a physical exam, a review of symptoms, and the results of multiple blood tests which will detect low testosterone levels.

Male hypogonadism is usually treated with testosterone replacement to return testosterone levels to normal and natural therapies which will increase testosterone production including diet and exercise, weight loss, improved sleep.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Male Hypogonadism treatment such as Leflutrozole, LPCN-1111, Testagen and others. Key players involved in the development of therapies to treat Male Hypogonadism are Hypospraypharma, Mereo BioPharma, Lipocine Inc, Clarus Therapeutics Inc, Lennham Pharmaceuticals Inc and others. Three drugs are under late-stage Phase II clinical trials and five drugs are in Phase I clinical trials and some other drugs are under Preclinical stages of development.

Report Highlights

Global Insight Service's, Male Hypogonadism - Drug Pipeline Landscape, 2023 report provides an overview of the Male Hypogonadism pipeline drugs. This report covers detailed insights on Male Hypogonadism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Male Hypogonadism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Male Hypogonadism - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Male Hypogonadism
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Male Hypogonadism - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase II
5.1.1 Leflutrozole
5.1.2 LPCN-1111
5.1.3 Testagen
5.2 Clinical Stage Drugs - Phase I
5.2.1 Anti-Androgens
5.2.2 CKD-845
5.2.3 DNL-0300
5.2.4 SOL-924
5.2.5 Testosterone Undecanoate
5.3 Clinical Stage Drugs - Preclinical
5.3.1 ACE-167
5.3.2 Deuterated-Testosterone
5.3.3 nTc Nanoparticle
5.3.4 TSX-049
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Chong Kun Dang Pharmaceutical
9.2 Clarus Therapeutics Inc
9.3 Diurnal Limited
9.4 EndoCeutics Inc
9.5 Function Promoting Therapies LLC
9.6 Hypospraypharma
9.7 IASO BioMed Inc
9.8 Lennham Pharmaceuticals Inc
9.9 Lipocine Inc
9.10 Mereo BioPharma
9.11 Solural Pharma ApS
9.12 TesoRx Pharma LLC
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1.2 Number of Products under Development by Male Hypogonadism
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details - DNL-0300/Diurnal Limited
Table 2.2 Clinical Trial Details - Leflutrozole/Mereo BioPharma
Table 2.3 Clinical Trial Details - CKD-845/Chong Kun Dang Pharmaceutical
Table 2.4 Clinical Trial Details - Testagen/Hypospraypharma
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products under Development for Male Hypogonadism, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Male Hypogonadism, 2023
Figure 1.3 Products by Top 5 Mechanism of Action for Male Hypogonadism, 2023
Figure 1.4 Products by Top 5 Molecule Type for Male Hypogonadism, 2023
Figure 1.5 Products by Top 5 Route of Administration for Male Hypogonadism, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings